Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.1%

In this article:

Amicus Therapeutics, Inc. FOLD was a big mover last session, as the company saw its shares rise more than 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $21.72 to $23.24 in the past one-month time frame.

The company has seen two negative estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Amicus Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Amicus Therapeutics, Inc. Price

Amicus Therapeutics, Inc. Price
Amicus Therapeutics, Inc. Price

Amicus Therapeutics, Inc. price | Amicus Therapeutics, Inc. Quote

A better-ranked stock in the Medical – Biomedical and Genetics industry is Pharma Mar, S.A. PHMMF, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Legal Marijuana: An Investor’s Dream

Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.

Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.

Download Marijuana Moneymakers FREE >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report
 
PHARMA MAR SA (PHMMF) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement